Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 5/2021

01-05-2021 | Breast Cancer | Breast Cancer (AS Zimmer, Section Editor)

Role of Platinums in Triple-Negative Breast Cancer

Authors: Filipa Lynce, Raquel Nunes

Published in: Current Oncology Reports | Issue 5/2021

Login to get access

Abstract

Purpose of Review

Platinum compounds are used in the treatment of various types of cancer. Here, we review the current role of cisplatin and carboplatin in the treatment of early stage and advanced triple-negative breast cancer (TNBC), and the use of biomarkers in predicting response to platinum therapy.

Recent Findings

Addition of carboplatin to a neoadjuvant chemotherapy regimen can result in improvement in the pathological complete response rates. The long-term benefit of the addition of carboplatin to standard chemotherapy regimens remains unproven. Single-agent platinum is an option in the treatment of advanced breast cancer. BRCA1/2 mutations predicted benefit from platinums in advanced, but not early stage breast cancer. There are yet no biomarkers to predict response to platinum in sporadic TNBC.

Summary

Platinum compounds are an option in the treatment of TNBC. Identification of biomarkers to select tumors most likely to derive benefit from these agents is still needed. Ongoing trials are exploring the role of platinum in the adjuvant setting and in combination with other agents, including immune checkpoint inhibitors.
Literature
1.
Bardal SK, Waechter JE, Martin, DS. Applied pharmacology. Elsevier/Saunders. 2011
2.
3.
4.
5.
6.
Byrski T, Huzarski T, Dent R, Marczyk E, Jasiowka M, Gronwald J, et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Can Res Treat. 2014;147:401–5.
7.
Turner N, Tutt A, Ashworth A. Hallmarks of “BRCAness” in sporadic cancer. Nat Rev Cancer. 2004;4(10):814–9.CrossRef
8.
• Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72 This trial level analysis was conducted to assess whether pathological complete response could be used as a surrogate endpoint for EFS or OS.CrossRef
9.
Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, et al. Association of event-free and distant recurrence–free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial. JAMA Oncol. Published online July 23, 2020. doi:https://​doi.​org/​10.​1001/​jamaoncol.​2020.​2535
10.
Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020;6(5):1–9.CrossRef
11.
Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810–21.CrossRef
12.
Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;30(8):1279. https://​doi.​org/​10.​1093/​annonc/​mdz158.
13.
Rugo HS, Olopade OI, DeMichele A, Yau C, van’t Veer LJ, et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med. 2016;375(1):23–34.
14.
•• Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33(1):13–21 This phase III trial examined the impact of adding carboplatin and/or bevacizumab in the pCR rate and long-term outcomes for patients with early stage TNBC.CrossRef
15.
Golshan M, Cirrincione CT, Sikov WM, Berry DA, Jasinski S, Weisberg TF, et al. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Ann Surg. 2015;262(3):434–9.
16.
Sikov WM, Polley MY, Twohy E, Perou CM, Singh B, Berry DA et al. CALGB (alliance) 40603: long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC). J Clin Oncol. 2019; 37, no. 15_suppl, 591-591.
17.
Katherine A Hoadley, Bradford C. Powell, Dona Kanavy, David Marron, Lisle E. Mose, Terry Hyslop, Donald A. Berry, Olwen Hahn, Sara M. Tolaney, William M. Sikov, Charles M. Perou, Lisa A. Carey. Mutational analysis of triple-negative breast cancer (TNBC): CALGB 40603 (Alliance) [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P4-05-03
18.
Von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomized phase 2 trial. Lancet Oncol. 2014;15(7):747–56.CrossRef
19.
Hahnen E, Lederer B, Hauke J, Loibl S, Krober S, Scheeweiss A, et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncol. 2017;3(10):1378–85.CrossRef
20.
Loibl S, Weber KE, Timms KM, Elkin EP, Hahnen E, Fasching PA, et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann Oncol. 2018;29(12):2341–7.
21.
Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2014;33:983–91.CrossRef
22.
23.
Telli M, Metzger O, Timms K, Evans B, Vogel D, et al. Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. J Clin Oncol. 2018;15:519–9.
24.
Gianni L, Huang C, Egle D, et al. Pathologic complete response to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. 2019 San Antonio Breast Cancer Symposium. Abstract GS3-04. Presented December 12, 2019.
25.
Sharma P, Lopez-Tarruella S, Garcia-Saenz JA, Khan QJ, Gomez HL, Prat A, et al. Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel. Clin Cancer Res. 2018;24(8):1845–52.CrossRef
26.
Sharma P, Kimler BF, O’Dea A, Nye LE, Wang YY, Yoder R, et al. Results of randomized phase II trial of neoadjuvant carboplatin plus docetaxel or carboplatin plus paclitaxel followed by AC in stage I-III triple negative breast cancer. J Clin Oncol. 2019;37(15_suppl):516.CrossRef
27.
Tung N, Arun B, Hacker MR, Hofstatter E, Toppmeyer DL, et al. TBCRC 031: randomized phase ii study of neoadjuvant cisplatin versus doxorubicin-cyclophosphamide in germline BRCA carriers with HER2-negative breast cancer (the INFORM trial). J Clin Oncol. 2020 May 10;38(14):1539–48.CrossRef
28.
Tung NM, Boughey JC, Pierce LJ, Robson ME, Bedrosian I, Dietz JR, et al. Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J Clin Oncol. 2020;38:2080–106.
29.
Burstein HJ, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30(10):1541–57.
30.
Isakoff SJ, Mayer E, He L, Traina TA, Carey LA, Krag KJ, et al. TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol. 2015;33(17):1902–9.CrossRef
31.
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67.
32.
•• Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial. Nat Med. 2018;24(5):628–37 This phase III randomized patients with metastatic breast cancer to carboplatin or docetaxel in the first-line setting.CrossRef
33.
Sharma P, Rodler E, Barlow WE, Gralow J, Huggins-Puhalla SL, et al. Results of a phase II randmozined trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416). Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 1001-1001
34.
O’Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2014;32(34):3840–7.CrossRef
35.
Yardley DA, Coleman R, Conte P, Cortes J, Brufsky A, Shtivelband M, et al. Nab-paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Ann Oncol. 2018;29:1763–70.
36.
Lander EM, Lehmann BD, Shah PD, Dees EC, Ballinger TJ, et al. A phase II trial of atezolizumab (anti-PD-L1) with carboplatin in patients with metastatic triple-negative breast cancer (mTNBC). DOI: 10.1200/JCO.2020.38.15_suppl.TPS1112 Journal of Clinical Oncology 38, no. 15.
37.
Vidula N, Nanda R, Miller K, Abramson V, Pohlmann P, et al. Abstract OT2-04-05: pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease: Translational Breast Cancer Research Consortium (TBCRC) 44 trial. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr OT2-04-05.
38.
Telli M, Timms KM, Reid J, Hennessy B, Mills GB, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22(15):3764–73.CrossRef
Metadata
Title
Role of Platinums in Triple-Negative Breast Cancer
Authors
Filipa Lynce
Raquel Nunes
Publication date
01-05-2021
Publisher
Springer US
Published in
Current Oncology Reports / Issue 5/2021
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-021-01041-x

Other articles of this Issue 5/2021

Current Oncology Reports 5/2021 Go to the issue

Palliative Medicine (A Jatoi, Section Editor)

Global Perspectives on Palliative Care for Cancer Patients: Not All Countries Are the Same

Breast Cancer (AS Zimmer, Section Editor)

Rare Breast Cancer Subtypes

Orthopedic Oncology (JA Abraham, Section Editor)

Giant Cell Tumor of Bone: An Update

Breast Cancer (AS Zimmer, Section Editor)

Integrating Adjuvant Radiation with Post-Neoadjuvant Therapies in Early Breast Cancer

Breast Cancer (AS Zimmer, Section Editor)

Emerging Therapeutics for Patients with Triple-Negative Breast Cancer

Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)

Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits